MNKD

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company founded in 1991 and headquartered in Westlake Village, California. The company has transformed from a single-product diabetes-focused entity into a diversified biopharmaceutical company with multiple revenue streams. MannKind specializes in developing and commercializing inhaled therapeutic products using its proprietary <b>Technosphere</b> drug delivery platform, primarily targeting endocrine disorders and orphan lung diseases. The company went public in 2004 and has evolved significantly over the past two decades, particularly accelerating its diversification strategy since 2022.